MASS earnings analysis
What we found in MASS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
908 Devices delivered $16.074 million of revenue, beating the $15.3352 million consensus estimate, and raised the low end of full-year 2026 revenue guidance to $68.0 million. However, diluted EPS of negative $0.32 missed the negative $0.14 estimate, while net loss from continuing operations was $11.894 million. NIRLAB results were included following the May 4, 2026 acquisition, but the filing provides no material changes to previously disclosed risk factors and does not provide sufficient information to assess current-quarter margins, balance-sheet trends, or cash flow.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Beat Estimates
- Revenue was $16.074 million, approximately $0.739 million or 4.8% above the $15.3352 million consensus estimate. The filing's reported revenue was also above the $13 million shown for 2026 Q1 in the provided quarterly history.
- Revenue Outlook Raised
- The company raised the low end of full-year 2026 revenue guidance by $1.0 million, to $68.0 million-$70.0 million from $67.0 million-$70.0 million previously.
- NIRLAB Results Included
- NIRLAB was acquired on May 4, 2026, and its results were included in the unaudited consolidated financial statements for the three and six months ended June 30, 2026.
- Disclosure Controls Effective
- Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- EPS Miss and Persistent Losses
- Net loss from continuing operations was $11.894 million, and diluted EPS of negative $0.32 missed the negative $0.14 consensus estimate by $0.18, indicating continued earnings volatility despite the revenue beat.
- Acquisition Integration Risk
- The May 4, 2026 NIRLAB acquisition adds integration and control complexity; management stated it intends to exclude NIRLAB from its internal-control evaluation as of December 31, 2026.
- Executive Share-Sale Plans
- Two executives adopted Rule 10b5-1 trading plans covering potential sales of up to 16,459 shares for the CFO and 44,251 shares for the Senior Vice President of Sales & Product Marketing. The plans expire on August 10, 2027 and December 31, 2026, respectively.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.32
What they said about what is next.
Full-year 2026 revenue outlook was raised at the low end to $68.0 million-$70.0 million from $67.0 million-$70.0 million previously, implying approximately 21%-25% year-over-year growth. No quantitative EPS outlook was provided.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 6, 2026
- In Q1 2026, 908 Devices (MASS) reported revenues of $13.4 million, marking a 14% increase compared to $11.8 million in Q1 2025, although it resulted in a net loss of $12.0 million, up from $9.8 million year-over-year.…
- 10-K · March 9, 2026
- 908 Devices positions itself as a provider of handheld, point-of-need chemical analysis leveraging proprietary microscale mass spectrometry (HPMS) and complementary optical spectroscopy to address health, safety and…
- 10-Q · November 10, 2025
- 908 Devices reported Q3 2025 revenue of $14,005,000, a slight decline from $14,519,000 in Q3 2024, but an increase from $13,000,000 in Q2 2025. Despite reporting a loss of $14,982,000, an improvement from a larger loss…
- 10-Q · August 5, 2025
- 908 Devices reported Q2 revenue of $13,035,000 (up from $11,462,000 in Q2 2024, +13.8%) and gross profit of $6,373,000 (gross margin 48.9%). The company recorded a loss from continuing operations of $12,908 (net loss…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MASS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever